Irinotecan
Stage IV Uterine Corpus Cancer AJCC v8
M.D. Anderson Cancer CenterSmall moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
48 Active assets in the Stage IV Uterine Corpus Cancer AJCC v8 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin City of Hope Medical Center | Phase 3 | BB |
Bms-907351 M.D. Anderson Cancer Center | Phase 2 | BB |
Olaparib National Cancer Institute (NCI) | Phase 2 | B |
Nivolumab M.D. Anderson Cancer Center | Phase 2 | B |
Tak-228 National Cancer Institute (NCI) | Phase 2 | B |
View all 50 →
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →